Business
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from
About this update from Phathom Pharmaceuticals, Inc.
[{"type":"text","content":"Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and modification of term debt Providing FY 2026 guidance; operating profitability expected beginning in Q3 2026 and for FY 2026 Management to host conference call today, February 26, 2026, at 8:00 a.m. EST FLORHAM PARK, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 financial guidance. “We are pleased with our continued growth throughout 2025, leveraging the efficiency of our GI-focused strategy,” said Steven Basta, President and Chief Executive Officer of Phathom. “Revenue increased significantly over the last three quarters. In the fourth quarter, we realigned our sales organization and enter 2026 with a stronger sales team and marketing initiatives designed to deepen engagement and increase prescribing for GERD across gastroenterologists.” “Phathom exited 2025 with strong revenue growth and meaningful progress on expense discipline initiatives,” said Sanjeev Narula, Chief Financial and Business Officer of Phathom. “Following our January financing, we negotiated a modification to our term loan to reduce interest and extend maturity. We believe these steps provide us with an enhanced capital structure and financial flexibility as we position Phathom for anticipated operating profitability beginning in the third quarter 2026. We are executing with discipline to drive revenue growth and anticipate reaching cash flow positivity in 2027.” Recent Business Highlights and Fourth Quarter and Full Year 2025 Results VOQUEZNA Commercial Progress: Phathom completed its sales force realignment in the fourth quarter. Phathom’s sales force is currently at >95% strength, having filled most of the open sales positions in recent weeks. In the fourth quarter, Phathom recruite...